## REGN: Regeneron Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.48 indicates fundamental undervaluation. Quality metrics strong (ROE 15%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($738.32)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference**
- Source: The Manila Times | 20251222T211557 | Neutral | Relevance: 100%
- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 2:15 p.m. Pacific Time. The presentation will be accessible via Regeneron's investor relations website, with a replay and transcript archived for at least 30 days. Regeneron is a leading biotechnology company focused on developing life-transforming medicines for serious diseases.

**2. Voya Investment Management LLC Cuts Stake in Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251220T140825 | Somewhat-Bearish | Relevance: 100%
- Voya Investment Management LLC reduced its stake in Regeneron Pharmaceuticals, Inc. by 26.2% in the third quarter, selling 45,270 shares and ending with 127,536 shares valued at approximately $71.71 million. Several institutional investors adjusted their positions in REGN, with some increasing and others acquiring new stakes. Company insiders have also been selling shares, while Wall Street analysts maintain a "Moderate Buy" consensus rating with a target price of $779.45.

**3. Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Thrivent Financial for Lutherans**
- Source: MarketBeat | 20251220T110830 | Neutral | Relevance: 100%
- Thrivent Financial for Lutherans significantly reduced its stake in Regeneron Pharmaceuticals, selling 93.1% of its shares in Q2 2025, while company insiders also made notable sales. Despite this, analysts maintain a "Moderate Buy" rating with a consensus price target of $779.45, as Regeneron exceeded Q3 earnings estimates. The company's stock currently trades around $768, boasting a market cap of approximately $80.7 billion.

**4. Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Corient Private Wealth LLC**
- Source: MarketBeat | 20251220T085745 | Somewhat-Bullish | Relevance: 100%
- Corient Private Wealth LLC reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 21.4% in the second quarter, selling 4,688 shares. In contrast, several other major institutions like Dodge & Cox and State Street Corp significantly increased their holdings, with institutional ownership now at 83.31%. Analysts maintain a "Moderate Buy" rating for REGN with a consensus price target of $779.45.

**5. Should Regeneronâ€™s Clarified Eylea Biosimilar Timeline Reshape How REGN Investors View Its Core Franchise?**
- Source: Simply Wall Street | 20251220T032851 | Neutral | Relevance: 100%
- Regeneron recently settled with Alvotech and Teva over AVT06, an Eylea biosimilar, setting a U.S. entry date for late 2026 or potentially earlier. This agreement clarifies the timeline for biosimilar competition, reducing legal uncertainty but reinforcing the need for Regeneron to diversify beyond its core Eylea franchise. The focus now shifts to other Regeneron therapies, such as Lynozyfic for multiple myeloma, to offset future revenue pressure from biosimilars.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $768 | $767 | +0% |
| 2025-12-10 | Wells Fargo | $745 | $700 | +6% |
| 2025-12-04 | Canaccord Genui | $1057 | $850 | +24% |
| 2025-12-04 | BMO Capital | $850 | $725 | +17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-04 | Canaccord Genui | main | Buy |
| 2025-12-04 | BMO Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 9 ($97.67M) |
| Sells | 15 ($32.83M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (-4.0%)
- Blackrock Inc.: 8.6% (-4.7%)
- JPMORGAN CHASE & CO: 7.9% (+106.7%)
- State Street Corpora: 4.5% (-2.9%)
- Dodge & Cox Inc.: 4.4% (+18.9%)

### Key Risks

1. Heavy insider selling: $33M sold (15 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 5 raises (avg +13%) could attract flows.
- Momentum building: MRS_20 improving +2.9% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.48 suggests fair value with growth premium. Quality metrics strong (margin 32%). Balance sheet: strong liquidity (4.1x), low leverage (D/E 0.30), $1.4B free cash flow. Analyst sentiment positive (5 raises, avg +13%). Insider buying signal ($97.7M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $82.6B |
| Beta | 0.37 |
| 52W Range | $476.49 - $790.98 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.48 |
| Forward P/E | 20.3 |
| Current P/E | 18.0 |
| YoY Growth | -11.2% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from 0.9% to 3.8% (+2.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.2pp (needs >4.0% for momentum thesis). MRS_5 at 1.4% confirms short-term momentum alignment. AM_20 at 4.4% shows strong absolute momentum above own 20MA. Outperforming sector by 3.9pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). Elevated volume (1.3x 20MA), institutional activity likely. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.80% (CS: 78) | Neutral |
| RSI_14 | 66.7 | Neutral |
| MACD Histogram | 0.11 | Bullish |
| vs SMA20 | 1.044x | Above |
| vs SMA50 | 1.142x | Above |
| vs SMA200 | 1.296x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $779.36
- **Stop Loss:** $738.32 (5.3% risk)
- **Target:** $861.44 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 29
- **Position Value:** $22,601.44
- **Portfolio %:** 22.60%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-03 (Est: $10.77)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.64 | $11.83 | +22.7% |
| 2025Q2 | $8.44 | $12.89 | +52.7% |
| 2025Q1 | $8.48 | $8.22 | -3.0% |
| 2024Q4 | $11.19 | $12.07 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*